ibuprofen

Overview

Ibuprofen is a propionic acid-derived non-steroidal anti-inflammatory drug (NSAID) widely used for its analgesic, antipyretic, and anti-inflammatory properties. It exerts its pharmacological effects primarily through reversible inhibition of cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the biosynthesis of prostaglandins and thromboxanes involved in pain signaling, fever induction, and inflammatory cascades. Available in numerous formulations — including immediate-release tablets, lysinate salts, and sustained-release compositions — ibuprofen occupies a central role in both prescription and over-the-counter (OTC) pain and fever management, with non-prescription use typically capped at a maximum daily dose of 1,200 mg. Beyond its classical analgesic indication, ibuprofen has attracted sustained scientific interest for its potential utility in oncology, infectious disease, drug delivery, and environmental monitoring, positioning it as a molecularly versatile compound across multiple biomedical domains.

As a small-molecule NSAID, ibuprofen belongs to the same pharmacological class as indomethacin, naproxen, Diclofenac, ketoprofen, and mefenamic acid — agents with which it is frequently compared in pharmacokinetic, ecological, and clinical studies. Its broad tissue distribution and relatively short half-life make formulation optimization an active area of pharmaceutical research, while its widespread consumption and incomplete environmental metabolism have established it as a prototypical pharmaceutical micropollutant of global concern.

Focus of Latest Publications

Recent publications on ibuprofen have focused largely on formulation optimization, delivery strategies, and repurposing beyond conventional analgesic use. Two pharmacokinetic studies evaluated modified-release oral products designed to reduce dosing frequency. A biphasic 400 mg immediate-release/sustained-release tablet showed bioequivalent total and peak exposure to reference immediate-release ibuprofen after single dosing, and equivalent steady-state exposure after repeated dosing, while food did not significantly affect absorption. In a related in vivo and virtual pharmacokinetic analysis, an immediate-release/sustained-release bi-layer tablet maintained plasma concentrations above predefined therapeutic thresholds for longer than immediate-release formulations, supporting prolonged pain and fever relief with fewer daily doses.

Several studies examined ibuprofen in advanced dosage forms and manufacturing platforms. Semi-solid extrusion 3D printing using milk formula as the main excipient produced pediatric chewable dosage forms containing ibuprofen, with dose accuracy scaling linearly with print weight and dissolution showing modestly improved ibuprofen release from the milk matrix. In another manufacturing-focused study, membrane percrystallization was used to crystallize ibuprofen microcrystals with high yield, stable Form I purity, low residual solvent and moisture, and improved flowability compared with commercial ibuprofen, indicating potential for integrated crystallization and particle engineering.

Ibuprofen was also investigated in combination therapies and local delivery systems. In a rat model of Staphylococcus aureus-induced keratitis, eye drops containing levofloxacin plus ibuprofen produced the lowest expression of inflammatory mediators, metalloproteinases, corneal angiogenesis markers, and Bax, with histology showing the best therapeutic outcomes among the tested groups. For osteoarthritis, ibuprofen-loaded mesoporous silica nanoparticles were incorporated into injectable thermoresponsive hydrogels for intra-articular delivery; these systems enabled rapid ibuprofen release, sustained resveratrol release, and in a papain-induced rat model reduced inflammatory cytokines including interleukin-6, lowered oxidative stress markers, and improved joint architecture, with the MCM-41-based formulation performing better than the SBA-15-based system.

Beyond therapeutic delivery, ibuprofen has appeared in studies of analytical methods and broader biomedical screening. An eco-friendly HPTLC method was validated for simultaneous determination of erdosteine, ibuprofen, and pseudoephedrine in a pharmaceutical combination used for upper respiratory tract infection symptoms. In cancer research, connectivity map screening identified ibuprofen as a candidate that could enhance osimertinib activity and help overcome resistance in patient-derived lung cancer organoids and TKI-resistant cell models.

Key Publications

NEWJul Development of a Biphasic Modified-Release Ibuprofen Tablet Formulation: Single-Dose and Multiple-Dose Pharmacokinetics and Food-Effect Studies. (Clinical and translational science, 2026, PMID 42374602): "Ibuprofen is the most commonly used NSAID; however, its short biological half-life, reflected in the short duration of pain relief, limits the comfortableness of its usage."
NEWJun A novel eco-friendly HPTLC approach for the simultaneous determination of erdosteine, ibuprofen and pseudoephedrine pharmaceutical combination. (Scientific reports, 2026, PMID 42303778): "This drug combination aids in treating symptoms associated with upper respiratory tract infections (URTIs) by providing mucolytic, analgesic, anti-inflammatory, and decongestant effects within a single therapeutic regimen."
May Graphene-Based Electrochemical Sensors for the Determination of Pharmaceutical- and Agricultural-Based Emerging Contaminants in Water. (Analytical chemistry, 2026, PMID 42060697): "Under optimized electro-Fenton (EF) conditions, additional ECs—including diclofenac, ibuprofen, glyphosate, and estradiol—showed comparable responses, demonstrating broad applicability independent of molecular structure."
Jun Semi-solid extrusion 3D printing of milk formula-based paediatric chewable dosage forms. (Journal of pharmaceutical sciences, 2026, PMID 42031026): "The platform was loaded either with pure drugs namely, paracetamol (PCT), sodium valproate (SDVT), ibuprofen (IBU) and carbamazepine (CBZ), or with powders compounded from commercial tablets."
Apr An eye drop combination for treating Staphylococcus aureus-induced keratitis in rats: repurposing ibuprofen. (Scientific reports, 2026, PMID 42031955): "The current study aimed to test a combination of levofloxacin and ibuprofen for treating Staphylococcus aureus-associated keratitis, with special emphasis on the potential antimicrobial and antibiofilm activities of the non-steroidal anti-inflammatory drug (NSAID) moiety."
May Ecotoxicological assessment of Zantedeschia aethiopica (L.) and Eisenia foetida Savigny exposure to pharmaceutical and personal care products, and hazelnut shell. (The Science of the total environment, 2026, PMID 41965162): "Caffeine, ibuprofen, losartan, and triclosan are pseudo persistent contaminants, generating chronic toxicity, and hydrolysis of organic support as porous media could cause effects on biotic components (plants and earthworms) of biofilters."
May Integrated crystallization, drying, and particle engineering of ibuprofen microcrystals with enhanced flowability using percrystallization. (International journal of pharmaceutics, 2026, PMID 41941942): "In this study, PerX was evaluated for ibuprofen crystallization under different feed concentrations and temperatures."
May Development of injectable ibuprofen and resveratrol co-loaded mesoporous silica nanoparticle-based hydrogels for sustained delivery in osteoarthritis management. (Journal of pharmaceutical sciences, 2026, PMID 41839392): "These drug‐loaded MSNs were formulated into thermoresponsive injectable hydrogels (M41IFRSG and S15IFRSG) for intra‐articular delivery to achieve localised therapy for osteoarthritis (OA)."
May Patient-derived malignant effusion organoids guide tailored therapy and dissect third-generation EGFR-tyrosine kinase inhibitor resistance mechanisms in lung cancer. (Cancer letters, 2026, PMID 41740831): "Connectivity Map (CMap) screening revealed that the candidate ibuprofen could enhance the anti-tumor activity of osimertinib and overcome the resistance, validated in PDO and TKI-resistant lung cancer cell models."
May Optimizing ibuprofen dosing: insights from in vivo and virtual pharmacokinetic trials. (European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2026, PMID 41720357): "This study systematically compared four ibuprofen formulations: immediate-release (IR) 400 mg tablets, IR 200 mg tablets, lysinate salt equivalent to 400 mg ibuprofen, and a novel bi-layer tablet integrating immediate- and sustained-release (IR/SR) components."